In our first update of the Decentralised Clinical Trials (DCT) Adoption Tracker for 2022, we saw three notable trends on telemedicine, use of DCT among institutions and non-profit organisations, as well as among small and medium-sized CROs. The DCT Adoption Tracker analyses 12 years of data based on clinical registry protocols, research papers, and press releases to find trends on the uptake of decentralisation approaches.
Data from the first three months of 2022 shows telemedicine use in clinical trials is set to continue gaining momentum. To date, 70% of trials involving decentralisation have included telemedicine in 2022, compared to less than half in 2019.
There is also the continued rise of institutions and non-profit organisations utilising decentralisation. Between January and March this year, 10% of new trials involving institutions or non-profits in high-income countries used decentralised trial elements, compared to 5% in 2019. In contrast, just 7% of trials with commercial sponsors have included decentralisation so far this year.
Last year saw a dramatic increase in the use of decentralisation by small and medium-sized CROs, a trend which has continued in the first three months of 2022. Since the beginning of 2021, 13% of trials involving small or medium-sized CROs have used decentralisation. This is in comparison to just 8% of trials featuring large CROs, including only seven trials so far in 2022.
Revisit or discover our DCT Adoption Tracker with Q1 updates here. Our tracker pinpoints what type of sponsors are leading DCT adopters, as well as which decentralisation approaches are most used. We analyse DCT data across different countries and different indications. We aim to update the tracker periodically to keep you abreast on DCT trends. You can sign up to our newsletter so you won't miss the latest.